PURPOSE: Patients with colorectal cancers (CRC) and high microsatellite instability (MSI) have a better outcome than their chromosome-unstable counterpart. Given the heterogeneity of microsatellite-unstable CRCs, we wanted to see whether any MSI-associated molecular features are specifically associated with prognosis. EXPERIMENTAL DESIGN: One hundred and nine MSI-high CRCs were typed for primary mismatch repair (MMR) defect and for secondary loss of MMR proteins. Frameshifts at seven target genes, mutations in the RAS pathway, and methylation at MLH1/CDKN2A promoters were also searched. The interplay of molecular findings with clinicopathologic features and patient survival was analyzed. RESULTS: Of 84 MLH1-deficient CRCs, 31 (36.9%) had MSH3 and 11 (13.1%) had MSH6 loss (P < 0.001), biallelic frameshift mutations at mononucleotide repeats accounting for most (78%) MSH3 losses. As compared with MSH3-retaining cancers, MLH1-deficient tumors with MSH3 loss showed a higher number of mutated target genes (3.94 ± 1.56 vs. 2.79 ± 1.75; P = 0.001), absence of nodal involvement at pathology [N0; OR, 0.11; 95% confidence interval (CI), 0.04-0.43, P < 0.001], and better disease-free survival (P = 0.06). No prognostic value was observed for KRAS status and for MLH1/CDKN2A promoter methylation. The association between MSH3 loss and N0 was confirmed in an independent cohort of 71 MLH1-deficient CRCs (OR, 0.23; 95% CI, 0.06-0.83, P = 0.02). CONCLUSIONS: MLH1-deficient CRCs not expressing MSH3 have a more severe MSI, a lower rate of nodal involvement, and a better postsurgical outcome.
PURPOSE:Patients with colorectal cancers (CRC) and high microsatellite instability (MSI) have a better outcome than their chromosome-unstable counterpart. Given the heterogeneity of microsatellite-unstable CRCs, we wanted to see whether any MSI-associated molecular features are specifically associated with prognosis. EXPERIMENTAL DESIGN: One hundred and nine MSI-high CRCs were typed for primary mismatch repair (MMR) defect and for secondary loss of MMR proteins. Frameshifts at seven target genes, mutations in the RAS pathway, and methylation at MLH1/CDKN2A promoters were also searched. The interplay of molecular findings with clinicopathologic features and patient survival was analyzed. RESULTS: Of 84 MLH1-deficient CRCs, 31 (36.9%) had MSH3 and 11 (13.1%) had MSH6 loss (P < 0.001), biallelic frameshift mutations at mononucleotide repeats accounting for most (78%) MSH3 losses. As compared with MSH3-retaining cancers, MLH1-deficient tumors with MSH3 loss showed a higher number of mutated target genes (3.94 ± 1.56 vs. 2.79 ± 1.75; P = 0.001), absence of nodal involvement at pathology [N0; OR, 0.11; 95% confidence interval (CI), 0.04-0.43, P < 0.001], and better disease-free survival (P = 0.06). No prognostic value was observed for KRAS status and for MLH1/CDKN2A promoter methylation. The association between MSH3 loss and N0 was confirmed in an independent cohort of 71 MLH1-deficient CRCs (OR, 0.23; 95% CI, 0.06-0.83, P = 0.02). CONCLUSIONS:MLH1-deficient CRCs not expressing MSH3 have a more severe MSI, a lower rate of nodal involvement, and a better postsurgical outcome.
Authors: Ryan D Morin; Karen Mungall; Erin Pleasance; Andrew J Mungall; Rodrigo Goya; Ryan D Huff; David W Scott; Jiarui Ding; Andrew Roth; Readman Chiu; Richard D Corbett; Fong Chun Chan; Maria Mendez-Lago; Diane L Trinh; Madison Bolger-Munro; Greg Taylor; Alireza Hadj Khodabakhshi; Susana Ben-Neriah; Julia Pon; Barbara Meissner; Bruce Woolcock; Noushin Farnoud; Sanja Rogic; Emilia L Lim; Nathalie A Johnson; Sohrab Shah; Steven Jones; Christian Steidl; Robert Holt; Inanc Birol; Richard Moore; Joseph M Connors; Randy D Gascoyne; Marco A Marra Journal: Blood Date: 2013-05-22 Impact factor: 22.113
Authors: Luigi Laghi; Francesca Negri; Federica Gaiani; Tommaso Cavalleri; Fabio Grizzi; Gian Luigi De' Angelis; Alberto Malesci Journal: Int J Mol Sci Date: 2020-12-18 Impact factor: 5.923
Authors: Sofia Sagredou; Panagiotis Dalezis; Eirini Papadopoulou; Maria Voura; Maria V Deligiorgi; Michail Nikolaou; Mihalis I Panayiotidis; George Nasioulas; Vasiliki Sarli; Dimitrios T Trafalis Journal: Pharmaceutics Date: 2021-06-15 Impact factor: 6.321
Authors: Christoph Campregher; Gerald Schmid; Franziska Ferk; Siegfried Knasmüller; Vineeta Khare; Benedikt Kortüm; Kyle Dammann; Michaela Lang; Theresa Scharl; Andreas Spittler; Andres I Roig; Jerry W Shay; Christopher Gerner; Christoph Gasche Journal: PLoS One Date: 2012-11-27 Impact factor: 3.240
Authors: Manuela Pinheiro; Carla Pinto; Ana Peixoto; Isabel Veiga; Paula Lopes; Rui Henrique; Helena Baldaia; Fátima Carneiro; Raquel Seruca; Ian Tomlinson; Michal Kovac; Karl Heinimann; Manuel R Teixeira Journal: Br J Cancer Date: 2015-08-06 Impact factor: 7.640